Latest Trustworthy News from Dr. Mercola - delivered straight to your inbox!

NYT: Mediocre COVID-19 Drug Will Still Be a Blockbuster

Gilead Sciences’ COVID-19 treatment drug, remdesivir, has already brought in $873 million since its emergency use authorization, making it the company’s second best-selling drug for the third quarter. The thing is, it’s a “mediocre” drug at best. According to The New York Times, Dr. Peter B. Bach, director of the Center for Health Policy and Outcomes at Memorial Sloan Kettering Cancer Center, said “This is a troubling approval … an extremely weak set...

Read the Full Article for Free!

You can unsubscribe at any time and I guarantee the privacy of your email. View our privacy policy

Subscribe for FREE to the #1 Natural Health Newsletter or Login for Instant Access

Unlock censored health information that Google doesn't want you to read

Keep your privacy secure — we are one of the few websites that have banned all Google and Facebook scripts to help stop their surveillance capitalism

Get access to all of Dr. Mercola's health articles, E-books and special reports